SAFC Installs Continuous-Flow Reactor - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SAFC Installs Continuous-Flow Reactor

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

SAFC Commercial, the custom manufacturing services business unit of Sigma-Aldrich, has installed a new commercial-scale continuous flow reactor at its Sheboygan, Wisconsin facility with capacity to produce up to 150 kg of product per day. Now fully operational, the reactor is complemented by a smaller pilot-scale continuous flow reactor that is being fabricated at the nearby Milwaukee, Wisconsin facility to carry out process optimization studies and manufacturing capability of up to 30 kg of product per day.
 
"These capabilities give customers access to products synthesized through reactions that were previously impractical or impossible to do with a conventional batch platform," said Andreas Weiler, director of global strategic marketing for SAFC, in a press release. "The reactors will allow SAFC to develop or scale up flow reactions for customers, eliminating the need for customers to install in-house flow capacity. This is also a much greener technology and substantially reduces the amount of chemicals and solvents employed in reactions."
 
Continuous flow manufacturing is a lean manufacturing platform that provides customers access to as little or as much of a product as needed. The nature of this technique offers safer, seamless scale-up of a wider array of reactions compared to the batch platform. Additionally, this technique may aid customers in achieving process control, while helping to eliminate batch failures and minimize risks associated with handling hazardous chemicals.

Source: Sigma-Aldrich

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here